1. Home
  2. ANGH vs SCYX Comparison

ANGH vs SCYX Comparison

Compare ANGH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anghami Inc.

ANGH

Anghami Inc.

N/A

Current Price

$3.18

Market Cap

35.6M

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.92

Market Cap

41.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGH
SCYX
Founded
2012
1999
Country
United Arab Emirates
United States
Employees
186
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.6M
41.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ANGH
SCYX
Price
$3.18
$0.92
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
1.8K
384.2K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.57
52 Week High
$7.05
$1.29

Technical Indicators

Market Signals
Indicator
ANGH
SCYX
Relative Strength Index (RSI) 45.26 44.35
Support Level $2.83 $0.69
Resistance Level $4.00 $0.96
Average True Range (ATR) 0.23 0.06
MACD -0.06 -0.02
Stochastic Oscillator 47.34 4.91

Price Performance

Historical Comparison
ANGH
SCYX

About ANGH Anghami Inc.

Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: